Phase 1 Biliary Tract Cancer Clinical Trials
18 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–18 of 18 trials
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting
Phase 1Phase 2
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Biliary Tract CancerMelanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.124 enrolled1 locationNCT06708663
Recruiting
Phase 1Phase 2
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.102 enrolled43 locationsNCT06431490
Recruiting
Phase 1
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Metastatic Biliary Tract CarcinomaMetastatic Biliary Tract Cancer
Washington University School of Medicine48 enrolled1 locationNCT07107750
Recruiting
Phase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 1
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 1Phase 2
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Biliary Tract Cancer
Akeso135 enrolled1 locationNCT06938321
Recruiting
Phase 1
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more
SEED Therapeutics, Inc.171 enrolled6 locationsNCT07197554
Recruiting
Phase 1Phase 2
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Metastatic Biliary Tract Cancer
M.D. Anderson Cancer Center50 enrolled1 locationNCT06548412
Recruiting
Phase 1
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Breast CancerBiliary Tract CancerOvarian Cancer+1 more
NextCure, Inc.145 enrolled14 locationsNCT06774963
Recruiting
Phase 1Phase 2
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 1
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
Biliary Tract CancerCholangiocarcinoma
University of Maryland, Baltimore15 enrolled2 locationsNCT06546969
Recruiting
Phase 1
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins25 enrolled1 locationNCT06564623
Recruiting
Phase 1Phase 2
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Pancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)Gastric or Gastroesophageal Junction Adenocarcinoma
Phanes Therapeutics258 enrolled11 locationsNCT05482893
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+4 more
ModeX Therapeutics, An OPKO Health Company115 enrolled6 locationsNCT06239194
Recruiting
Phase 1Phase 2
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
Biliary Tract CancerHead and Neck Squamous Cell CarcinomaSolid Tumor
TiumBio Co., Ltd.140 enrolled11 locationsNCT05784688
Recruiting
Phase 1Phase 2
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Biliary Tract CancerOvarian CancerGastric Carcinoma+4 more
Evopoint Biosciences Inc.240 enrolled1 locationNCT06792435
Recruiting
Phase 1Phase 2
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Yonsei University44 enrolled1 locationNCT05749900